The College of American Pathologists (CAP) convened an expert panel to develop the upcoming evidence-based guideline “Evaluation of Measurable Residual Disease in B-Lymphoblastic Leukemia.”
The draft consists of eight statements: three strong recommendations, two conditional recommendations, and three good practice statements. The list of key questions and references included for data extraction are available for review on
cap.org.During the open comment period, the expert panel will conduct a refresh of the literature search to include newer articles published since the initial literature search was performed. The expert panel will review and consider all comments received as well as additional data from the literature refresh to finalize the recommendations and Good Practice Statements. The guideline manuscript will be submitted to
Archives of Pathology & Laboratory Medicine later.
Reviewing and commenting on the draft recommendations and Good Practice Statements should take ~20 minutes to complete.
We thank you in advance for your participation.
Genevieve Marie Crane, MD, PhD, FCAP
Evaluation of MRD B-ALL, Co-chair
Alexandra Kovach, MD, FCAP
Evaluation of MRD B-ALL, Co-chair
Mary Kay Washington, MD, PhD, FCAP
Center Guideline Committee, Chair
For more information visit
cap.org. 